Loading clinical trials...

IPC-CALF Versus GEKO in Post-op Total Hip Patients | Clinical Trials | Clareo Health

WITHDRAWNNA

IPC-CALF Versus GEKO in Post-op Total Hip Patients

Comparison of Intermittent Pneumatic Compression (IPC) of the Calf and gekoTM Neuromuscular Electrostimulation (NMES) Device on Lower Limb Circulation Following Elective Total Hip Replacement (THR)

NCT02425917•Firstkind Ltd

View on ClinicalTrials.gov

Summary

This study is designed to compare the effect of IPC on post-operative circulation in lower limbs with gekoTM device after total hip replacement procedure.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male and Female
•2. Aged over 18-80 years
•3. Be in good general health and fitness other than the clinical requirement for a planned hip replacement.
•4. Free of significant abnormal findings as determined by medical history (specifically an absence of DVT or haematological disorders.
•5. No history or signs of drug abuse (including alcohol), licit or illicit.
•6. Has not used any medications (prescribed or over-the-counter including herbal remedies) judged to be significant by the Principal Investigator (PI) during the thirty (30) days preceding the study.
•7. Able to understand the Patient Information Sheet and willing to sign the written Informed Consent Form.
•8. Able and willing to follow the protocol requirements.

Exclusion Criteria

•1. Are requiring hip revision surgery
•2. History or signs of significant haematological disorders (especially in relation to clotting or coagulation or previous deep or superficial vein thrombosis/pulmonary embolism).
•3. Significant Peripheral arterial disease (ABPI \< 0.8), varicose veins or lower limb ulceration or ischemia.
•4. Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or knee replacement).
•5. Recent trauma to lower limb.
•6. Chronic Obesity (BMI Index \>40kg/m2).
•7. Pregnancy.
•8. Significant history of following diseases i. Cardiovascular: Recent MI (\< 6 months) ii. Percutaneous Coronary Intervention (PCI) with stent (\< 3 months for Bare metal stent (BMS) and \< 12 months for Drug Eluding Stent (DES) iii. Moderate to severe CCF, uncontrolled AF iv. Neurological: Stroke, Hemiplegia/Paraplegia, Myopathies v. Renal: Moderate to severely impaired renal function vi. Hepatic: Moderate to severely impaired hepatic function vii. Psychiatric disorders viii. Dermatological conditions affecting lower limbs ix. Haematological conditions i.e. coagulation disorders, sickle cell disease
•9. A pulse rate of less than 40 beats/minute
•10. A sitting systolic blood pressure \>180 and \<100 mmHg and/or a sitting diastolic pressure of \>100 mmHg.
+2 more criteria

Key Dates

Start Date

June 1, 2017

Primary Completion Date

December 1, 2017

Completion Date

January 1, 2018

Last Updated

July 21, 2017

Conditions

Total Hip Replacement

Interventions

geko

DEVICE

IPC-Calf

DEVICE

Effectiveness of Telerehabilitation in Continuity With Outpatient Physiotherapy After Total Hip Replacement.

NCT06238960

Total Hip ReplacementTelerehabilitation+1 more

View study

RECRUITING

Post-Market Observational Study of the HARMONY® Evolution Implants and Instruments

NCT06628336

Total Hip Replacement

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 21, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

IPC-CALF Versus GEKO in Post-op Total Hip Patients

Inclusion Criteria

Exclusion Criteria

Effectiveness of Telerehabilitation in Continuity With Outpatient Physiotherapy After Total Hip Replacement.

Post-Market Observational Study of the HARMONY® Evolution Implants and Instruments

Dressing-related Experiences and Surgical Site Self-care in Hip and Knee Replacement: an Observational Cohort Study

Evaluation of Conventional Antibiotic Prophylaxis During a Change of Hip or Knee Infected at a Time

Effectiveness of PENG Block Combined to LFCN Block on the Quality of Recovery After Total Hip Replacement

Digital Healthcare App After Total Hip Arthroplasty